Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Big Pharma Split's Total Stockholders Equity for the quarter that ended in Dec. 2025 was C$18.27 Mil. Big Pharma Split's Total Assets for the quarter that ended in Dec. 2025 was C$31.84 Mil.
Therefore, Big Pharma Split's Equity to Asset Ratio for the quarter that ended in Dec. 2025 was 0.57.
The historical rank and industry rank for Big Pharma Split's Equity-to-Asset or its related term are showing as below:
TSX:PRM'
s Equity-to-Asset Range Over the Past 10 Years
Min: 0.51 Med: 0.58 Max: 0.6
Current: 0.57
During the past 9 years, the highest Equity to Asset Ratio of Big Pharma Split was 0.60. The lowest was 0.51. And the median was 0.58.
TSX:PRM's Equity-to-Asset is not ranked
in the Asset Management industry.
Industry Median: 0.83
vs TSX:PRM: 0.57
Big Pharma Split (TSX:PRM) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Big Pharma Split Equity-to-Asset Related Terms
Big Pharma Split Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Big Pharma Split's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSX:PRM vs BLK, BX, KKR: Equity-to-Asset Comparison
For the Asset Management subindustry, Big Pharma Split's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Big Pharma Split Equity-to-Asset vs Asset Management Industry
For the Asset Management industry and Financial Services sector, Big Pharma Split's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Big Pharma Split's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Big Pharma Split's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Big Pharma Split (TSX:PRM) has a Equity-to-Asset of 0.57 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Big Pharma Split and its competitors. This is near median its historical median of 0.58. Over the past decade, Big Pharma Split's Equity-to-Asset has ranged from 0.51 to 0.60.
Is Big Pharma Split's Equity-to-Asset too high?
Big Pharma Split's current Equity-to-Asset of 0.57 is near median its 10-year median of 0.58. Over the past 10 years, this metric has ranged from a low of 0.51 to a high of 0.60. The Asset Management industry median Equity-to-Asset is 0.83. Big Pharma Split's value of 0.57 is 31.3% below this industry median. Overall, Big Pharma Split has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does Big Pharma Split's Equity-to-Asset compare to BLK and BX?
Big Pharma Split's Equity-to-Asset of 0.57 can be compared against companies in the Asset Management industry. The industry median Equity-to-Asset is 0.83. Big Pharma Split's value of 0.57 is 31.3% below this benchmark. Historically, Big Pharma Split's own Equity-to-Asset has ranged from 0.51 to 0.60 over the past decade. While the company's 10-year median is 0.58 vs. the industry median of 0.83, Big Pharma Split has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for an Asset Management company?
The median Equity-to-Asset among Asset Management companies is 0.83, based on 1,629 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Big Pharma Split's current Equity-to-Asset of 0.57 is 31.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Big Pharma Split and its competitors. For the Asset Management industry, the median Equity-to-Asset is 0.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Big Pharma Split's current Equity-to-Asset is 0.57, which is near median its own 10-year median of 0.58. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Big Pharma Split stock overvalued right now?
Big Pharma Split (TSX:PRM) has a current Equity-to-Asset of 0.57. The stock's GF Value™ is C$1.80, compared to a current price of C$11.61 — trading 545% above its estimated fair value. The current Equity-to-Asset is 0.57, which is near median its 10-year median of 0.58 and 31.3% below the Asset Management industry median of 0.83. Big Pharma Split's overall GF Score™ is 7/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Big Pharma Split (TSX:PRM), the current Equity-to-Asset is 0.57 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Big Pharma Split (TSX:PRM) Overvalued in 2026?
Based on GuruFocus' analysis, Big Pharma Split stock appears to be overvalued.
The current stock price of C$11.61 is trading 545% above its estimated GF Value™ of C$1.80.
Key valuation signals for TSX:PRM:
Equity-to-Asset: 0.57 (near median its 10-year median of 0.58)
GF Value™: C$1.80 vs. price of C$11.61 (545% above fair value)
Industry Position: 31.3% below the Asset Management median
No single metric tells the full story. See the TSX:PRM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Big Pharma Split Corp is a closed end mutual fund corporation. The investment objective of the company is to provide shareholders with fixed cumulative preferential quarterly cash distributions and regular monthly cash distributions. The company has a presence in the United States, France, and the United Kingdom.
7GF Score
Get the complete analysis for TSX:PRM
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:PRM has been successfully added to your 
